Advertisement

T-cell receptor gene-modified cells: past promises, present methodologies and future challenges

Published:January 14, 2019DOI:https://doi.org/10.1016/j.jcyt.2018.12.002

      Abstract

      Immunotherapy constitutes an exciting and rapidly evolving field, and the demonstration that genetically modified T-cell receptors (TCRs) can be used to produce T-lymphocyte populations of desired specificity offers new opportunities for antigen-specific T-cell therapy.
      Overall, TCR-modified T cells have the ability to target a wide variety of self and non–self targets through the normal biology of a T cell. Although major histocompatibility complex (MHC)–restricted and dependent on co-receptors, genetically engineered TCRs still present a number of characteristics that ensure they are an important alternative strategy to chimeric antigen receptors (CARs), and high-affinity TCRs can now be successfully engineered with the potential to enhance therapeutic efficacy while minimizing adverse events. This review will focus on the main characteristics of TCR gene-modified cells, their potential clinical application and promise to the field of adoptive cell transfer (ACT), basic manufacturing procedures and characterization protocols and overall challenges that need to be overcome so that redirection of TCR specificity may be successfully translated into clinical practice, beyond early-phase clinical trials.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Barrett D.M.
        • Grupp S.A.
        • June C.H.
        Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street.
        J Immunol. 2015; 195: 755-761
        • Morris E.C.
        • Stauss H.J.
        Optimizing T-cell receptor gene therapy for hematologic malignancies.
        Blood. 2016; 127: 3305-3311
      1. Novartis. Novartis receives first ever FDA approval for a CAR-T cell therapy, KymriahTM (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice [press release].

      2. Gilead. Kite's Yescarta™ (Axicabtagene Ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy [press release].

        • Kuhns M.S.
        • Davis M.M.
        • Garcia K.C.
        Deconstructing the Form and Function of the TCR/CD3 Complex.
        Immunity. 2006; 24: 133-139
        • Wucherpfennig K.W.
        • Gagnon E.
        • Call M.J.
        • Huseby E.S.
        • Call M.E.
        Structural biology of the T-cell receptor: insights into receptor assembly, ligand recognition, and initiation of signaling.
        Cold Spring Harb Perspect Biol. 2010; 2a005140
        • Chen L.
        • Flies D.B.
        Molecular mechanisms of T cell co-stimulation and co-inhibition.
        Nat Rev Immunol. 2013; 13: 227-242
        • Gaud G.
        • Lesourne R.
        • Love P.E.
        Regulatory mechanisms in T cell receptor signalling.
        Nat Rev Immunol. 2018; 18: 485-497
        • Spear T.T.
        • Nagato K.
        • Nishimura M.I.
        Strategies to genetically engineer T cells for cancer immunotherapy.
        Cancer Immunol Immunother. 2016; 65: 631-649
        • Ye B.
        • Stary C.M.
        • Gao Q.
        • Wang Q.
        • Zeng Z.
        • Jian Z.
        • et al.
        Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
        J Immunol Res. 2017; 20175210459
        • Harris D.T.
        • Kranz D.M.
        Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
        Trends Pharmacol Sci. 2016; 37: 220-230
        • Esensten J.H.
        • Helou Y.A.
        • Chopra G.
        • Weiss A.
        • Bluestone J.A
        CD28 Costimulation: From Mechanism to Therapy.
        Immunity. 2016; 44: 973-988
        • Purbhoo M.A.
        • Irvine D.J.
        • Huppa J.B.
        • Davis M.M.
        T cell killing does not require the formation of a stable mature immunological synapse.
        Nat Immunol. 2004; 5: 524-530
        • Manz B.N.
        • Jackson B.L.
        • Petit R.S.
        • Dustin M.L.
        • Groves J.
        T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters.
        Proc Natl Acad Sci USA. 2011; 108: 9089-9094
        • Artyomov M.N.
        • Lis M.
        • Devadas S.
        • Davis M.M.
        • Chakraborty A.K
        CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery.
        Proc Natl Acad Sci USA. 2010; 107: 16916-16921
        • Gilham D.E
        • et al.
        Adoptive T-cell therapy for cancer in the United Kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.
        Hum Gene Ther. 2015; 26: 276-285
        • Karpanen T.
        • Olweus J
        T-cell receptor gene therapy–ready to go viral?.
        Mol. Oncol. 2015; 9: 2019-2042
        • Ikeda H.
        T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells: Table 1.
        Int. Immunol. 2016; 28: 349-353
        • Duong C.P.M.
        • Yong C.S.M.
        • Kershaw M.H.
        • Slaney C.Y.
        • Darcy P.K.
        Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
        Mol. Immunol. 2015; 67: 46-57
        • Schub A.
        • Schuster I.G.
        • Hammerschmidt W.
        • Moosmann A.
        CMV-specific TCR-transgenic T cells for immunotherapy.
        J. Immunol. 2009; 183: 6819-6830
        • Kah J.
        • et al.
        Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.
        J. Clin. Invest. 2017; 127: 3177-3188
        • Banu N.
        • et al.
        Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections.
        Sci. Rep. 2014; 4: 4166
        • Joseph A.
        • et al.
        Lentiviral Vectors Encoding Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Receptor Genes Efficiently Convert Peripheral Blood CD8 T Lymphocytes into Cytotoxic T Lymphocytes with Potent In Vitro and In Vivo HIV-1-Specific Inhibitory Activity.
        J. Virol. 2008; 82: 3078-3089
        • Morgan R.A
        • et al.
        Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes.
        Science. 2006; 314: 126-129
        • Duval L.
        • et al.
        Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.
        Clin. Cancer Res. 2006; 12: 1229-1236
        • Johnson L.A.
        • et al.
        Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
        Blood. 2009; 114: 535-546
        • van den Berg J.H.
        • et al.
        Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.
        Mol. Ther. 2015; 23: 1541-1550
        • Morgan R.A.
        • et al.
        High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
        J. Immunol. 2003; 171: 3287-3295
        • Kuball J.
        • et al.
        Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.
        Immunity. 2005; 22: 117-129
        • Rapoport A.P.
        • et al.
        NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
        Nat. Med. 2015; 21: 914-921
        • Park J.
        • Zhong S.
        • Krogsgaard M.
        • Mazumder A.
        MAGE-A3 Specific T-Cell Receptor Adoptive Cell Transfer of Multiple Myeloma.
        Blood. 2012; 120
        • Kageyama S.
        • et al.
        Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer.
        Clin. Cancer Res. 2015; 21: 2268-2277
        • Border E.
        • et al.
        Abstract 2564: Selection of affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10.
        Cancer Res. 2018; 78: 2564
        • Draper L.M.
        • et al.
        Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
        Clin. Cancer Res. 2015; 21: 4431-4439
        • Jin B.Y.
        • et al.
        Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
        JCI insight. 2018; 3 ([Epub ahead of print])
        • Stone J.D.
        • Harris D.T.
        • Kranz D.M.
        TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
        Curr. Opin. Immunol. 2015; 33: 16-22
        • Linette G.P
        • et al.
        Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
        Blood. 2013; 122: 863-871
        • Leen A.M
        • et al.
        Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
        Blood. 2013; 121: 5113-5123
        • Stemberger C
        • et al.
        Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy.
        Blood. 2014; 124: 628-637
        • Peggs K.S
        • et al.
        Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
        Lancet. 2003; 362: 1375-1377
        • Thimme R
        • et al.
        CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection.
        J. Virol. 2003; 77: 68-76
        • Viganò S
        • et al.
        HLA-G+ HIV-1-specific CD8+ T cells are associated with HIV-1 immune control.
        AIDS. 2017; 31: 207-212
        • Mueller K
        • et al.
        Protective capacity of virus-specific T cell receptor-transduced CD8 T cells in vivo.
        J. Virol. 2012; 86: 10866-10869
        • Leibman R.S.
        • Riley J.L
        Engineering T Cells to Functionally Cure HIV-1 Infection.
        Mol. Ther. 2015; 23: 1149-1159
        • Parkin D.M.
        The global health burden of infection-associated cancers in the year 2002.
        Int. J. Cancer. 2006; 118: 3030-3044
        • Qasim W
        • et al.
        Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.
        J. Hepatol. 2015; 62: 486-491
        • McClary H.
        • Koch R.
        • Chisari F.V
        • Guidotti L.G.
        Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines.
        J. Virol. 2000; 74: 2255-2264
        • Guidotti L.G
        • et al.
        Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.
        Immunity. 1996; 4: 25-36
        • Rohaan M.W.
        • Wilgenhof S.
        • Haanen J.B.A.G.
        Adoptive cellular therapies: the current landscape.
        Virchows Arch. 2018; ([Epub ahead of print])https://doi.org/10.1007/s00428-018-2484-0
        • Linnemann C.
        • Schumacher T.N.M.
        • Bendle G.M.
        T-cell receptor gene therapy: critical parameters for clinical success.
        J. Invest. Dermatol. 2011; 131: 1806-1816
        • Jin J
        • et al.
        Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.
        J. Transl. Med. 2018; 16: 13
        • Grupp S.A
        • et al.
        Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia.
        N. Engl. J. Med. 2013; 368: 1509-1518
        • Cameron B.J
        • et al.
        Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
        Sci. Transl. Med. 2013; 5: 197ra103
        • Manning T.C.
        • Parke E.A.
        • Teyton L.
        • Kranz D.M.
        Effects of complementarity determining region mutations on the affinity of an alpha/beta T cell receptor: measuring the energy associated with CD4/CD8 repertoire skewing.
        J. Exp. Med. 1999; 189: 461-470
        • Robbins P.F
        • et al.
        Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
        J. Immunol. 2008; 180: 6116-6131
        • Wooldridge L
        • et al.
        A single autoimmune T cell receptor recognizes more than a million different peptides.
        J. Biol. Chem. 2012; 287: 1168-1177
        • Thomas S.
        • Stauss H.J.
        • Morris E.C.
        Molecular immunology lessons from therapeutic T-cell receptor gene transfer.
        Immunology. 2010; 129: 170-177
        • Wang X.
        • Rivière I.
        Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.
        Cancer Gene Ther. 2015; 22: 85-94
        • Hildinger M.
        • Abel K.L.
        • Ostertag W.
        • Baum C.
        Design of 5’ untranslated sequences in retroviral vectors developed for medical use.
        J. Virol. 1999; 73: 4083-4089
        • Kuball J
        • et al.
        Facilitating matched pairing and expression of TCR chains introduced into human T cells.
        Blood. 2007; 109: 2331-2338
        • Sommermeyer D.
        • Uckert W.
        Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells.
        J. Immunol. 2010; 184: 6223-6231
        • Cohen C.J.
        • Zhao Y.
        • Zheng Z.
        • Rosenberg S.A.
        • Morgan R.A.
        Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.
        Cancer Res. 2006; 66: 8878-8886
        • Hart D.P
        • et al.
        Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells.
        Gene Ther. 2008; 15: 625-631
        • Thomas S
        • et al.
        Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.
        J Immunol. 2007; 179: 5803-5810
      3. European Medicines Agency (EMA). Note for guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products (ICH Topic Q6B, CPMP/ICH/365/96) (effective from 01/09/1999).

        • Bravery C.A
        • et al.
        Potency assay development for cellular therapy products: an ISCT∗ review of the requirements and experiences in the industry.
        Cytotherapy. 2013; 15 (e9): 9-19
      4. European Medicines Agency (EMA). Guideline on human cell based medicinal products (CHMP/410869/2006) (effective from 01/09/2008).

      5. European Medicines Agency (EMA). Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer (CHMP/BWP/271475/2006 Rev.1) (effective from 01/09/2016).

      6. European Medicines Agency (EMA). Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells (CHMP/GTWP/671639/2008) (effective from 01/11/2012).

        • Biffi A
        • et al.
        Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy.
        Science. 2013; 3411233158
        • Aiuti A
        • et al.
        Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome.
        Science. 2013; 341 (–1233151)1233151
        • Cavazzana-Calvo M
        • et al.
        Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.
        Nature. 2010; 467: 318-322
        • Cartier N
        • et al.
        Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy.
        Science. 2009; 326: 818-823
        • Morris E.C
        • et al.
        Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult.
        Blood. 2017; 130: 1327-1335
        • Hacein-Bey-Abina S
        • et al.
        A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency.
        N Engl J Med. 2014; 371: 1407-1417
        • Huls M.H
        • et al.
        Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.
        J Vis Exp. 2013; 72: e50070https://doi.org/10.3791/50070
        • Singh H
        • et al.
        Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
        PLoS One. 2013; 8: e64138
        • Ahmadi M
        • et al.
        CD3 limits the efficacy of TCR gene therapy in vivo.
        Blood. 2011; 118: 3528-3537
        • Chang H.C
        • et al.
        A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments.
        Proc Natl Acad Sci USA. 1994; 91: 11408-11412
        • Kuball J
        • et al.
        Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain.
        J. Exp. Med. 2009; 206: 463-475
        • Morris E.C
        Editing gene engineering to enhance function.
        Blood. 2018; 131: 272-273
        • Legut M.
        • Dolton G.
        • Mian A.A.
        • Ottmann O.G.
        • Sewell A.K.
        CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.
        Blood. 2018; 131: 311-322
        • Okamoto S
        • et al.
        Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.
        Cancer Res. 2009; 69: 9003-9011
        • Provasi E
        • et al.
        Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer.
        Nat. Med. 2012; 18: 807-815
        • Voss R.-H
        • et al.
        Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells.
        Blood. 2010; 115: 5154-5163
        • Knies D
        • et al.
        An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.
        Oncotarget. 2016; 7: 21199-21221
        • Stone J.D
        • et al.
        A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.
        Cancer Immunol Immunother. 2014; 63: 1163-1176
        • Aggen D.H
        • et al.
        Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.
        Gene Ther. 2012; 19: 365-374
        • Zhou Q
        • et al.
        T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing.
        Blood. 2012; 120: 4334-4342
        • Zhu F
        • et al.
        Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
        Cytotherapy. 2018; 20: 394-406
        • Lock D
        • et al.
        Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.
        Hum Gene Ther. 2017; 28: 914-925
        • Mock U
        • et al.
        Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy.
        Cytotherapy. 2016; 18: 1002-1011
        • Jones B.S.
        • Lamb L.S.
        • Goldman F.
        • Di Stasi A.
        Improving the safety of cell therapy products by suicide gene transfer.
        Front. Pharmacol. 2014; 5: 254
        • Di Stasi A.
        • et al.
        Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy.
        N Engl J Med. 2011; 365: 1673-1683
        • Koh S
        • et al.
        A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus.
        Mol. Ther. Nucleic Acids. 2013; 2: e114
        • Dörrie J
        • et al.
        Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation.
        PLoS One. 2014; 9e109944
        • Balasiddaiah A
        • et al.
        Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.
        J. Virol. 2017; 91
        • Campillo-Davo D
        • et al.
        Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing.
        Front Immunol. 2018; 9: 2503
        • Fesnak A.D.
        • June C.H.
        • Levine B.L.
        Engineered T cells: the promise and challenges of cancer immunotherapy.
        Nat Rev Cancer. 2016; 16: 566-581
        • Beatty G.L.
        • Moon E.K.
        Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment.
        Oncoimmunology. 2014; 3e970027
        • Topalian S.L
        • et al.
        Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
        J Clin Oncol. 2014; 32: 1020-1030
        • Topalian S.L
        • et al.
        Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer.
        N. Engl. J. Med. 2012; 366: 2443-2454
        • Hamid O
        • et al.
        Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma.
        N. Engl. J. Med. 2013; 369: 134-144
        • Adachi K.
        • Tamada K.
        Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
        Cancer Sci. 2015; 106: 945-950
        • John L.B
        • et al.
        Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
        Clin Cancer Res. 2013; 19: 5636-5646
        • Rafiq S
        • et al.
        Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.
        Nat. Biotechnol. 2018; 36: 847-856
        • Palmer D.C
        • et al.
        Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
        J Immunol. 2004; 173: 7209-7216
        • Miao H
        • et al.
        EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
        PLoS One. 2014; 9: e94281
        • Gao J
        • et al.
        Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
        Cell. 2016; 167 (e9): 397-404
        • Zaretsky J.M
        • et al.
        Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
        N Engl J Med. 2016; 375: 819-829
        • Johnsen A.K.
        • Templeton D.J.
        • Sy M.
        • Harding C.V.
        Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis.
        J. Immunol. 1999; 163: 4224-4231
        • van Hall T
        • et al.
        Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
        Nat Med. 2006; 12: 417-424
        • Doorduijn E.M.
        • et al.
        TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
        J. Clin. Invest. 2016; 126: 784-794
        • Doorduijn E.M.
        • et al.
        T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.
        Oncoimmunology. 2018; 7e1382793
        • Gross G.
        • Waks T.
        • Eshhar Z.
        Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
        Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 10024-10028
        • Maude S.L.
        • Shpall E.J.
        • Grupp S.A.
        Chimeric antigen receptor T-cell therapy for ALL.
        Hematol. Am. Soc. Hematol. Educ. Progr. 2014; 2014: 559-564
        • June C.H.
        • O'Connor R.S.
        • Kawalekar O.U.
        • Ghassemi S.
        • Milone M.C.
        CAR T cell immunotherapy for human cancer.
        Science. 2018; 359: 1361-1365
        • Stone J.D.
        • Aggen D.H.
        • Schietinger A.
        • Schreiber H.
        • Kranz D.M.
        A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).
        Oncoimmunology. 2012; 1: 863-873
        • Watanabe K
        • et al.
        Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
        J. Immunol. 2015; 194: 911-920
        • Romero I
        • et al.
        The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.
        J. Pathol. 2012; 227: 367-379
        • Park J.
        • Thomas S.
        • Munster P.N.
        Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
        Epigenomics. 2015; 7: 641-652
        • Símová J
        • et al.
        Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status.
        Br. J. Cancer. 2011; 105: 1533-1541
        • Garrido F.
        • Aptsiauri N.
        • Doorduijn E.M.
        • Garcia Lora A.M.
        • van Hall T.
        The urgent need to recover MHC class I in cancers for effective immunotherapy.
        Curr. Opin. Immunol. 2016; 39: 44-51
        • Kim K
        • et al.
        Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
        Proc. Natl. Acad. Sci. U. S. A. 2014; 111: 11774-11779
        • Pili R
        • et al.
        Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).
        Clin. Cancer Res. 2017; 23: 7199-7208
        • Hasanali Z.S.
        • et al.
        Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
        Sci. Transl. Med. 2015; 7 (293ra102-293ra102)
        • Odunsi K
        • et al.
        Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer.
        Cancer Immunol. Res. 2014; 2: 37-49
        • Yao X
        • et al.
        Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.
        Blood. 2012; 119: 5688-5696
        • Morgan R.A
        • et al.
        Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy.
        J. Immunother. 2013; 36: 133-151
        • Moore T
        • et al.
        Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.
        Cancer Immunol. Immunother. 2018; 67: 311-325